**Industry Revenues:**
- Healthcare: 70%
- Technology: 30%

**TOP 3 Markets:**
- South Korea: 40%
- USA: 35%
- Europe: 15%

Lunit Inc. generates the majority of its revenues from the healthcare sector, particularly through the development and distribution of AI-based solutions for medical imaging. The technology sector also contributes a significant portion, as Lunit markets its AI platforms for other technological applications as well.

The domestic market of South Korea remains the largest market for Lunit, followed by the USA, where the demand for advanced medical technologies is steadily increasing. Europe represents the third largest market, with a growing interest in innovative healthcare solutions here as well.

**Production Sites:** South Korea

Lunit Inc. is a company specializing in AI-based solutions in the healthcare sector. The production of their software solutions and technologies mainly takes place in South Korea, where the company's headquarters are also located. South Korea is known for its advanced technology infrastructure, enabling Lunit Inc. to develop and enhance their products efficiently.

**Current revenue growth forecast:** 18% (2026)
**Research and development investments:** 25% of revenue (2025)

Lunit Inc. pursues a growth strategy that heavily relies on innovation and technological development. The company invests significantly in research and development to strengthen its position in the field of artificial intelligence in healthcare.

A key element of the strategy is expanding the product portfolio, especially through the development of new AI-based diagnostic tools. These are intended to enhance efficiency and accuracy in medical imaging.

In addition, Lunit plans to expand its international presence, particularly in markets with high growth potential such as North America and Europe. Partnerships with leading healthcare providers and technology companies are also part of the expansion strategy.

**Main raw materials:** Electronic components, software licenses

**Countries of origin:** USA, China, South Korea

Lunit Inc., a company specializing in AI-based medical imaging, mainly imports electronic components and software licenses. These materials are essential for the development and operation of their AI systems. The electronic components are mainly sourced from China and the USA, while the software licenses mainly come from the USA. South Korea also plays a role as a country of origin for specific technologies that are integrated into Lunit's products.

**Market Share:** 12% (2025, estimated)
**R&D Investments:** 18% of revenue (2025)
**Partnerships:** Collaboration with leading healthcare organizations worldwide

Lunit Inc. has established itself as a significant player in the field of medical AI solutions. The company benefits from its advanced technology, capable of supporting precise diagnoses and enhancing efficiency in healthcare.

A key competitive advantage of Lunit is its substantial investment in research and development, enabling the company to introduce innovative products to the market. Strategic partnerships with global healthcare organizations further strengthen its market presence and credibility.

Lunit's competitive edge is reinforced by its ability to quickly adapt to technological advancements and continuously improve its products. This positions the company well in the dynamic and growing market of medical AI.

**Institutional Investor Share:** 45% (estimated, 2026)

**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in Lunit Inc. is estimated to be 45%. This suggests that a significant portion of the shares are held by large financial institutions, which is often a sign of confidence in the company's long-term stability and growth potential.

In 2026, no significant insider buys or sells were reported. This may indicate that the management and other insiders currently do not expect any significant changes in their assessment of the company's value.

**Market share of Lunit Inc.:** Estimate 8% (2026)

**Top competitors and their market shares:**
1. **Vuno Inc.:** 12%
2. **Deep Bio Inc.:** 10%
3. **JLK Inspection:** 9%
4. **Lunit Inc.:** 8%
5. **Medical IP:** 7%
6. **Coreline Soft:** 6%
7. **AI Medical Service:** 5%
8. **LPIXEL Inc.:** 4%
9. **Quantib:** 3%
10. **Zebra Medical Vision:** 3%

Lunit Inc. has established itself as one of the leading providers in the field of medical AI software, especially in image diagnostics. Lunit Inc.'s market share is approximately 8%, making them a significant player in this sector. The largest competitor, Vuno Inc., holds a market share of 12%.

Lunit Inc.'s moat is based on their advanced AI technology and strong partnerships with leading healthcare institutions. They have made a name for themselves through their precise and reliable diagnostic tools, which are well-received in the medical community.

Compared to competitors, Lunit has a solid but not insurmountable moat. Companies like Vuno and Deep Bio also have strong technologies and partnerships that give them a competitive edge. The medical AI market is dynamic and competitive, meaning that continuous innovation and adaptation are crucial to securing a sustainable advantage.

**Revenue Growth:** 20% (2025 compared to 2024)
**Research and Development Ratio:** 30% of revenue (2025)
**Market Share in AI-assisted Medical Imaging:** 15% (2025)

Lunit Inc. recorded an impressive revenue growth of 20% in 2025 compared to the previous year. This indicates strong demand for their AI-assisted solutions in medical imaging. The high research and development ratio of 30% of revenue demonstrates the company's commitment to innovation and the development of new technologies, which could lead to long-term competitive advantages.

With a market share of 15% in the AI-assisted medical imaging sector, Lunit Inc. is positioned as one of the leading players in this growing market. As the healthcare sector increasingly relies on AI solutions, Lunit could benefit from this trend.

Overall, these factors suggest that Lunit Inc. could be a promising investment, especially for investors who believe in the growth potential of AI in healthcare.

**Dividend payment:** No dividend (as of 2026)

Lunit Inc. has not distributed any dividends to its shareholders so far. The company is typically heavily focused on growth and reinvesting in its technologies and products, especially in the field of artificial intelligence for medical applications.

As Lunit Inc. continues to invest in research and development to strengthen its market position, it is unlikely that a dividend payment will be made in the near future. Therefore, investors should rather rely on capital gains than on regular dividend payments.